JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

Начало・Списък с акции・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

20.89 4.19

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

20.63

Максимум

21.18

Ключови измерители
By Trading Economics
Приходи	11M -61M
Продажби	7.9M 46M
Марж на печалбата	-132.36
Служители	270
EBITDA	6.3M -58M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+84.25% upside

Дивиденти
By Dow Jones
Следващи печалби	2.03.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	726M 1.9B
Предишно отваряне	16.7
Предишно затваряне	20.89

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

9.91 / 14.15 Подкрепа & съпротива

Syndax Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

8.02.2026 г., 23:57 ч. UTC

Пазарно говорене

Uranium Outlook Heats Up on Rising Demand, Uncertain Supply -- Market Talk

8.02.2026 г., 23:47 ч. UTC

Пазарно говорене

Gold Rises Amid Growing U.S.-Iran Tensions -- Market Talk

8.02.2026 г., 23:43 ч. UTC

Пазарно говорене

Nikkei Likely to Rise Sharply After Takaichi's Election Win -- Market Talk

8.02.2026 г., 23:34 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

8.02.2026 г., 23:34 ч. UTC

Пазарно говорене

Landslide Election Victory of Japan's LDP Positive for Risk Assets -- Market Talk

8.02.2026 г., 23:26 ч. UTC

Пазарно говорене

Yen Skittish; Nikkei Jumps On LDP Landslide -- Market Talk

8.02.2026 г., 22:55 ч. UTC

Печалби

DBS Group 4Q Net S$2.36B Vs. Net S$2.62B >D05.SG

8.02.2026 г., 22:55 ч. UTC

Печалби

DBS Group 4Q Net Interest Income S$3.59B Vs. S$3.83B>D05.SG

8.02.2026 г., 22:55 ч. UTC

Печалби

DBS Board Proposes 4Q Dividend of 66 Singapore Cents/share>D05.SG

8.02.2026 г., 22:55 ч. UTC

Печалби

DBS Group: 2025 Total Dividend at S$3.06/share >D05.SG

8.02.2026 г., 22:55 ч. UTC

Печалби

DBS Group 4Q Net Weighed by Higher Tax Expense, Absence of Non-Recurring Gains Recrorded Last Year >D05.SG

8.02.2026 г., 22:55 ч. UTC

Печалби

DBS Group 4Q Total Income S$5.33B Vs. S$5.51B>D05.SG

8.02.2026 г., 21:43 ч. UTC

Пазарно говорене

FX Intervention Watch Resumes After Japan Election Result -- Market Talk

8.02.2026 г., 21:16 ч. UTC

Пазарно говорене

Right Of Australian Politics Reshaped as One Nation Surges -- Market Talk

8.02.2026 г., 21:15 ч. UTC

Пазарно говорене

Japan's Election Outcome to Revive Takaichi Trade -- Market Talk

7.02.2026 г., 09:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

7.02.2026 г., 09:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

7.02.2026 г., 05:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

7.02.2026 г., 02:46 ч. UTC

Придобивния, сливания и поглъщания

Big Money, High Anxiety -- Barrons.com

6.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

6.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

6.02.2026 г., 21:40 ч. UTC

Придобивния, сливания и поглъщания

Verizon Insiders Rarely Sell Company Stock. This Insider Just Did. -- Barrons.com

6.02.2026 г., 21:22 ч. UTC

Пазарно говорене

Mexico's Inflation Seen Accelerating in January -- Market Talk

6.02.2026 г., 21:17 ч. UTC

Печалби

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6.02.2026 г., 21:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

6.02.2026 г., 21:14 ч. UTC

Придобивния, сливания и поглъщания

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- Update

6.02.2026 г., 21:13 ч. UTC

Печалби

How the Software Panic Hit BDC Stocks -- and Why Some Might Be Worth Buying -- Barrons.com

6.02.2026 г., 21:13 ч. UTC

Печалби

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers -- Barrons.com

6.02.2026 г., 21:04 ч. UTC

Пазарно говорене

Gold Closes Out Volatile Week on Higher Note -- Market Talk

6.02.2026 г., 20:34 ч. UTC

Печалби

Tech Had an Awful Earnings Season. Other Stocks Are Saving the Day. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Syndax Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

84.25% нагоре

12-месечна прогноза

Среден 38.71 USD 84.25%

Висок 56 USD

Нисък 28 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Syndax Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

Купи

Задържане

Продай

Според 8 анализатори, дали борсови рейтинги на Syndax Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

9.91 / 14.15Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.